Vir Biotechnology, Inc.

Listed Company

VIRCIK 0001706431NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$68.56M

Net Income

$-437.99M

Total Assets

$1.00B

Equity

$765.28M

Shares Out

139.52M

Op. Cash Flow

$-391.78M

Business

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company that develops medicines that enhance the immune system to treat serious infectious diseases and cancer. The company’s main offerings are investigational monoclonal antibodies, small interfering RNA therapeutics, broadly neutralizing antibodies for HIV, and dual-masked T-cell engagers that leverage proprietary protein engineering and masking technologies. Its operations are organized around infectious disease programs (including HBV and HDV), oncology programs centered on masked TCEs, and core technology platforms (antibody discovery/AI and PRO-XTEN™ masking). VirBio conducts clinical development globally, partners with biopharma collaborators and CDMOs, and plans to commercialize through a mix of internal resources and third-party arrangements.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	69	74	86	1,616	1,095
Cost of revenue	26,000	845,000	3	146	66
Research and development	456	506	580	475	448
Selling, general and administrative	92	119	174	162	161
Restructuring, long-lived assets impairment and related charges, net	−182,000	35	14	0	—
Total operating expenses	548	661	770	783	675
Loss from operations	−479	−587	−684	833	421
Change in fair value of equity investments	2	−6	−22	−111	138
Interest income	40	72	87	28	—
Other expense, net	−409,000	−2	−9	4	−9
Total other income	42	64	56	−79	129
Loss before (provision for) benefit from income taxes	−438	−523	−628	754	550
(Provision for) benefit from income taxes	−217,000	1	13	−238	−21
Net loss	−438	−522	−615	516	—
Net loss attributable to noncontrolling interest	0	0	−56,000	0	—
Net loss attributable to Vir Bio	−438	−522	−615	516	529
Net loss per share attributable to VirBio, basic (in USD per share)	−3.16	−3.83	−4.59	3.89	4.07
Net loss per share attributable to VirBio, diluted (in USD per share)	−3.16	−3.83	−4.59	3.83	3.96
Weighted-average shares outstanding, basic (in shares)	139	136	134	133	130
Weighted-average shares outstanding, diluted (in shares)	139	136	134	135	133

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	232	223	242	849	348
Short-term investments	229	678	1,271	1,522	217
Restricted cash and cash equivalents, current	2	89	13	13	9
Equity investments	6	4	10	—	—
Prepaid expenses and other current assets	45	48	53	104	73
Total current assets	514	1,042	1,588	2,519	1,563
Intangible assets, net	8	8	23	33	33
Goodwill	17	17	17	17	17
Property and equipment, net	56	63	96	106	43
Operating right-of-use assets	62	60	71	83	87
Restricted cash and cash equivalents, noncurrent	7	6	6	7	7
Long-term investments	315	190	105	24	201
Other assets	25	12	12	15	3
TOTAL ASSETS	1,003	1,399	1,919	2,802	1,954
Accounts payable	10	5	6	6	7
Accrued and other liabilities	83	99	104	489	237
Contingent consideration obligation, current	0	16	0	—	0
Total current liabilities	93	120	175	511	341
Operating lease liabilities, noncurrent	89	90	112	124	134
Contingent consideration obligation, noncurrent	34	24	26	25	23
Other long-term liabilities	22	15	16	11	3
TOTAL LIABILITIES	238	248	329	724	522
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 139,474,954 and 136,959,446 shares issued and outstanding as of December 31, 2025 and 2024, respectively	14,000	14,000	13,000	13,000	13,000
Additional paid-in capital	1,965	1,912	1,829	1,710	1,572
Accumulated other comprehensive loss	−2	−2	−815,000	−9	−1
Accumulated deficit	−1,200	−760	−238	377	−139
TOTAL STOCKHOLDERS EQUITY	765	1,150	1,590	2,078	1,432
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	1,003	1,399	1,919	2,802	1,954

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	12	15	19	7	5
Amortization of premiums (accretion of discounts) on investments, net	9	5	−9	−9	−244,000
Noncash lease expense	5	5	8	9	6
Change in fair value of equity investments	−2	6	22	111	−138
Change in estimated fair value of contingent consideration	11	14	1	2	—
Payment of contingent consideration in excess of acquisition date fair value	−17	0	0	−94	−8
Stock-based compensation	49	78	111	102	84
In-process research and development impairment	0	15	10	0	—
Non-cash restructuring, long-lived assets impairment and related charges	654,000	24	8	0	—
Other non-cash items, net	172,000	−3	−910,000	—	—
Prepaid expenses and other current assets	2	4	36	−39	−4
Other assets	−13	353,000	2	−12	−1
Accounts payable	5	−988,000	732,000	797,000	−171,000
Accrued liabilities and other long-term liabilities	−10	−64	−359	−16	58
Operating lease liabilities	−7	−23	−13	−6	−535,000
Net cash used in operating activities	−392	−446	−779	1,663	−48
Proceeds from sale of equipment	253,000	3	0	22,000	0
Purchases of long-lived assets	−5	−7	−22	−68	−22
Purchases of investments	−886	−1,235	−2,016	−1,477	−420
Maturities and sales of investments	1,201	1,739	2,202	352	301
Net cash provided by investing activities	310	499	165	−1,193	−141
Proceeds from exercise of stock options	1	790,000	3	5	13
Proceeds from issuance of common stock under ESPP	3	4	4	3	2
Other financing activities	−361,000	−165,000	−287,000	−260,000	—
Net cash provided by financing activities	4	4	7	35	100
Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents	−78	57	−607	505	−88
Operating lease liabilities obtained in exchange of right-of-use asset	7	0	0	4	77

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro